Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trialZefei Jiang, Yuan Sheng, Haibo Wang et al.|Nature Medicine|2024Cited by 121
TORCHLIGHT: A randomized, double-blind, phase III trial of toripalimab versus placebo, in combination with nab-paclitaxel(nab-P) for patients with metastatic or recurrent triple-negative breast cancer (TNBC).Zefei Jiang, Quchang Ouyang, Tao Sun et al.|Journal of Clinical Oncology|2023Cited by 5
A plain language summary of results from the TORCHLIGHT trial of toripalimab plus chemotherapy for metastatic or recurrent triple-negative breast cancerYuan Sheng, Quchang Ouyang, Tao Sun et al.|Future Oncology|2024Cited by 1
A multicenter, prospective, non-interventional study to investigate the treatment patterns of neratinib in human epidermal growth factor receptor 2 positive (HER2+) early breast cancer (EBC) in China: Updated interim analysis from the NER-Tree study.Xiaojia Wang, Jin Zhang, Xinlan Liu et al.|Journal of Clinical Oncology|2025Cited by 0